Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs. Sanderling's unique approach combines a specialized investment focus with active management and long-term commitment to ensure the highest rates of return for both its entrepreneurs and investors. Sanderling emphasizes early-stage financing and active management of its portfolio companies. Sanderling and its principals play an active role in new ventures by providing seed and early-stage funding, contributing management leadership and administrative support, developing cost-control strategies to extend available dollars, supplying technical and regulatory expertise where needed, and offering the insight and perspective of those who have 'done it before.'
56
Total Investments
21
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Finance, Financial Services
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Sanderling Ventures
Recent Investments (56)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series C | •••••• | Apr 2025 | |
| Post-IPO Equity | •••••• | Jan 2024 | |
| Series B | •••••• | Jun 2021 | |
| Series D | •••••• | Mar 2021 | |
| Series C | •••••• | May 2020 | |
|
|
Series D | •••••• | Mar 2020 |
|
|
Series D | •••••• | Nov 2018 |
|
|
Series C | •••••• | Jan 2018 |
|
|
Seed Round | •••••• | Sep 2017 |
|
|
Series A | •••••• | Jul 2017 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.